Gilead Sciences (GILD) and its Kite unit have entered into a three-year cancer immunotherapy research collaboration with oNKo-innate. The goal: to discover and develop next-generation drug and engineered cell therapies focused on natural killer (NK) cells.Current cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play a critical role in the immune system. Both NK cells and T cells each have the potential to attack cancer cells, but each have different mechanisms for tumor cell killing.According to Gilead, appropriately activated and targeted NK cells …read more
Source:: Yahoo Finance
